Top

Published in:

01-09-2021 | Prostate Cancer | Original Article

Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy

Authors: Linda My Huynh, Emily Keit, Aviva Atri Schuller, Raymond Ceja Carrillo, Erica Huang, Thomas E. Ahlering, Shawna Boyle, Charles Enke, Michael J. Baine

Published in: World Journal of Urology | Issue 9/2021

Abstract

Objectives

To assess the impact of statin use on overall and time to biochemical failure following primary treatment of localized prostate cancer (PCa).

Subjects/patients and methods

1581 patients undergoing radical prostatectomy (RP) or radiation therapy (RT) for primary treatment of PCa between July 2007 and January 2020 were evaluated for statin use, demographic/oncologic characteristics, and biochemical outcomes. Rate of biochemical failure (BF) was assessed overall and at 1, 3, and 5 years; time to BF was estimated with Kaplan–Meier. Logistic and linear regression were used to control for treatment modality and disease characteristics.

Results

The average age was 63.0 ± 7.5 years and median pre-treatment PSA was 6.55 (IQR 4.94). 1473 (93.2%) and 108 (6.8%) underwent RP and RT, respectively. RP patients were younger, had lower pre-PSA, lower BMI, and lower risk disease. At 3.4 ± 2.7 years follow-up, 323 (20.4%) experienced BF. When stratified by statin use, BF overall and within 1, 3, and 5 years were not different. Time to BF, was lower in patients using statins (1.8 ± 1.9 years vs. 2.4 ± 2.6 years; p = 0.016). These results persisted in multivariate analysis, wherein statin use was not associated with BF but was associated with a shorter time to BF.

Conclusion

Overall, statin use was not associated with a reduced risk of BF in RP or RT patients. However, for patients with BF, statin use was associated with a decreased time to BF. Future investigations are warranted to further elucidate the impact of statin use on PCa recurrence.

Mann D, Reynolds K, Smith D, Muntner P (2008) Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42:1208–1215CrossRef

Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10–19PubMed

Kaushal V, Kohli M, Mehta P, Mehta JL (2003) Potential anticancer effects of statins: fact or fiction? Endothelium 10:49–58CrossRef

Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T (2011) Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 47:819–830CrossRef

Bawley O (2012) Prostate cancer epidemiology in the United States. World J Urol 30:195–200CrossRef

Meijer D, van Moorselaar JA, Vis AN, Bijnsdorp IV (2019) Prostate cancer development is not affected by statin use in patients with elevated PSA levels. Cancers 11:953CrossRef

Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomark Prev 16:2226–2232CrossRef

Kontraros M, Varkarakis I, Ntoumas K, Deliveliotis C (2013) Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 90:263–269CrossRef

Lyon TD, Turner RM, Yabes JG et al (2016) Preoperative statin use at the time of radical prostatectomy is not associated with biochemical recurrence or pathologic upgrading. J Urol 97:153–159CrossRef

10.

Keskivali T, Kujala P, Visakorpi R, Tammela TLJ, Murtola TJ (2016) Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate 76:469–478CrossRef

11.

Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams S (2013) Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int 111:954–962CrossRef

12.

Allott EH, Howard LE, Cooperberg MR et al (2014) Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 114:661–666CrossRef

13.

Yu O, Eberg M, Benayoun S et al (2014) Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32:5–11CrossRef

14.

Murtola TJ (2014) Statins and biochemical recurrence after radical prostatectomy—who benefits? BJU Int 114:634–638CrossRef

15.

Song C, Park S, Park J et al (2015) Statin use after radical prostatectomy reduces biochemical recurrence in menwith prostate cancer. Prostate 75:211–217CrossRef

16.

Raval AD, Thakker D, Negi H, Vyas A, Salkini MW (2016) Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 19:151–162CrossRef

17.

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(5):479–505CrossRef

18.

Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792–1802CrossRef

19.

Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH (2011) Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 14:63–68CrossRef

20.

Mass AY, Agalliu I, Laze J, Lepor H (2012) Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol 188:786–791CrossRef

21.

Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R et al (2013) Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 24:1427–1434CrossRef

22.

Scosyrev E, Tobis S, Donsky H et al (2012) Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int 111:E71–E77CrossRef

23.

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL (2010) Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 28:2653–2659CrossRef

24.

Zaorsky NG, Buyyounouski MK, Li T et al (2012) Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 84(1):e13–e17CrossRef

25.

Beesley LJ, Mordan TM, Spratt DE (2019) Individual and population comparisons of surgery and radiotherapy outcomes in prostate cancer using bayesian multistate models. AMA Netw Open 2(2):e187765CrossRef

26.

Lepor H (2000) Selecting candidates for radical prostatectomy. Rev Urol. 2(3):182–184 (186–189)PubMedPubMedCentral

27.

Rieken M, Kluth LA, Zylinas E et al (2013) Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 16:367–371CrossRef

28.

Lin MH, Chiu SY, Chang PH, Lai YL, Chen PC, Ho WC (2020) Hyperlipidemia and statins use for the risk of new diagnosed sarcopenia in patients with chronic kidney: a population-based study. Int J Environ Res Public Health 17:1494CrossRef

29.

Serban MC, Colantonio LD, Manthripradaga AD et al (2017) Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. Am Coll Cardiol 69:1386–1395CrossRef

30.

Carrao G, Ibrahim B, Nicotra F et al (2014) Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care 37(8):2225–2232CrossRef

31.

Yang CC, Jick SS, Testa MA (2003) Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol 55(3):288–298CrossRef

32.

Liu Z, Liu J, Shi X et al (2017) Comparing calculated free testosterone with total testosterone for screening and diagnosing late onset hypogonadism in aged males: a cross-sectional study. J Clin Lab Anal 31(5):1–7CrossRef

33.

Thompson IM, Goodman PJ, Tangen CM et al (2013) Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369:603–610CrossRef

Title: Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy
Authors: Linda My Huynh
Emily Keit
Aviva Atri Schuller
Raymond Ceja Carrillo
Erica Huang
Thomas E. Ahlering
Shawna Boyle
Charles Enke
Michael J. Baine
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Statins
Prostate Cancer
Prostatectomy
Prostatectomy
Published in: World Journal of Urology / Issue 9/2021
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-021-03600-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy

Abstract

Objectives

Subjects/patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Subjects/patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2021

Rectal perforation after aquablation of the prostate: lessons learned the hard way

The SIMULATE ureteroscopy training curriculum: educational value and transfer of skills

Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer

Retropulsion force in laser lithotripsy—an in vitro study comparing a Holmium device to a novel pulsed solid-state Thulium laser

Management of urinary extravasation after renal trauma: the need for multi-institutional prospective trials

COVID19: the response of the urologist